Literature DB >> 18024093

Biomarkers in drug discovery and development.

Ray Bakhtiar1.   

Abstract

Biomarkers have shown promising utilities at various stages of the pharmaceutical R & D. With the recent technological advancements and the introduction of protein and gene arrays, high performance instrumentation (e.g., high-field nuclear magnetic resonance and high-resolution mass spectrometers), and bioinformatics, decisions on safety and efficacy criteria can be made with a higher degree of confidence. However, there is a scarcity of robust and valid biomarkers to accelerate the drug development process from pre-clinical through all stages of clinical studies. In this article, a brief overview of current definitions, biomarker categories, challenges in biological and analytical validation, along with several clinical examples will be presented.

Mesh:

Substances:

Year:  2007        PMID: 18024093     DOI: 10.1016/j.vascn.2007.10.002

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  8 in total

1.  Criteria for environmentally associated autoimmune diseases.

Authors:  Frederick W Miller; K Michael Pollard; Christine G Parks; Dori R Germolec; Patrick S C Leung; Carlo Selmi; Michael C Humble; Noel R Rose
Journal:  J Autoimmun       Date:  2012-07-06       Impact factor: 7.094

2.  Biomarker- versus drug-driven tumor growth inhibition models: an equivalence analysis.

Authors:  Maria Luisa Sardu; Italo Poggesi; Giuseppe De Nicolao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-07-26       Impact factor: 2.745

3.  Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC.

Authors:  Karl Quint; Abbas Agaimy; Pietro Di Fazio; Roberta Montalbano; Claudia Steindorf; Rudolf Jung; Claus Hellerbrand; Arndt Hartmann; Helmut Sitter; Daniel Neureiter; Matthias Ocker
Journal:  Virchows Arch       Date:  2011-06-29       Impact factor: 4.064

4.  Mining biomarker information in biomedical literature.

Authors:  Erfan Younesi; Luca Toldo; Bernd Müller; Christoph M Friedrich; Natalia Novac; Alexander Scheer; Martin Hofmann-Apitius; Juliane Fluck
Journal:  BMC Med Inform Decis Mak       Date:  2012-12-18       Impact factor: 2.796

5.  Multidimensional mapping method using an arrayed sensing system for cross-reactivity screening.

Authors:  Sheryl E Chocron; Bryce M Weisberger; Hadar Ben-Yoav; Thomas E Winkler; Eunkyoung Kim; Deanna L Kelly; Gregory F Payne; Reza Ghodssi
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

6.  Prognostic accuracy of FIB-4, NAFLD fibrosis score and APRI for NAFLD-related events: A systematic review.

Authors:  Jenny Lee; Yasaman Vali; Jerome Boursier; Rene Spijker; Quentin M Anstee; Patrick M Bossuyt; Mohammad H Zafarmand
Journal:  Liver Int       Date:  2021-02       Impact factor: 5.828

7.  Improving clinical trial efficiency by biomarker-guided patient selection.

Authors:  Ruud Boessen; Hiddo J Lambers Heerspink; Dick De Zeeuw; Diederick E Grobbee; Rolf H H Groenwold; Kit C B Roes
Journal:  Trials       Date:  2014-04-02       Impact factor: 2.279

8.  The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach.

Authors:  John Jules O Mogaka; Moses J Chimbari
Journal:  PLoS One       Date:  2020-10-14       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.